BioTuesdays

Category - Markets

InspireMD
Markets

Rodman starts InspireMD at buy

Rodman & Renshaw has initiated coverage of InspireMD (NYSE MKT:NSPR) with a “buy” rating and 12-month price target of $4. The stock closed at 71 cents on Thursday. InspireMD is a commercial-stage company focusing on...

January 8, 2016
Avivagen
DevelopmentsMarkets

Avivagen issues letter to shareholders

In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans. Mr. Groome said Avivagen continues the process of commercializing its non...

January 8, 2016
Accelerate Diagnostics
Markets

WB starts Accelerate Diagnostics at outperform

William Blair has launched coverage of Accelerate Diagnostics (NASDAQ:AXDX) with an “outperform” rating and an “aggressive growth” company profile. The stock closed at $19.97 on Thursday. Analyst Brian Weinstein writes...

January 8, 2016
Codexis
Markets

HCW starts Codexis at buy

H.C. Wainwright has launched coverage of Codexis (NASDAQ:CDXS) with a “buy” rating and $6 price target. The stock closed at $4.23 on Tuesday. Codexis is a biotechnology services company that specializes in the...

January 6, 2016
novadaq
Markets

JMP resumes coverage of Novadaq at outperform

JMP Securities has resumed coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “market outperform” rating and $16 price target. The stock closed at $13.50 on Tuesday. “Novadaq was once highly regarded within...

January 6, 2016
Cynosure
Markets

Stifel ups Cynosure price target to $50

Stifel has raised its price target for Cynosure (NASDAQ:CYNO) to $50 from $44, reflecting revised estimates and an increased sales multiple due to the company’s higher growth rate. The stock closed at $42 on Monday...

January 5, 2016
Prima BioMed
Markets

Roth starts Prima BioMed at buy

Roth Capital Partners has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and price target of $6. The stock closed at $1.11 on Wednesday. “We believe Prima is in a leading position in the...

December 30, 2015
TetraLogic Pharmaceuticals
Markets

Roth starts TetraLogic Pharma at buy

Roth Capital Partners has launched coverage of TetraLogic Pharmaceutics (NASDAQ:TLOG) with a “buy” rating and price target of $5. The stock closed at $1.42 on Wednesday. Analyst Joseph Pantginis writes that TetraLogic...

December 30, 2015
oramed
Markets

Oramed closes licensing, investment deal in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has closed a license and investment deal with Hefei Tianhui Incubation of Technologies (HTIT) of China. Oramed has sold 1,155,367 restricted common shares to HTIT at a price of $10...

December 29, 2015